A prospective cohort study suggests that clinically meaningful quality‐of‐life changes continue well beyond the first postoperative year, with one‐year complications emerging as the strongest potentially modifiable predictor of later decline.
A UK trial-based economic evaluation found uncertain cost-effectiveness at 12 months, but a model extrapolating outcomes to 24 months estimated a lower cost per quality-adjusted life year for immediate surgery.
From breathier speech to breastfeeding history, metamaterial eye coils, and antifibrotic GLP-1 effects in mice, this week’s studies remind us that the most interesting signal is often hiding somewhere clinicians were not looking.